VANI

Over the past six months, Vivani Medical, Inc.'s stock price has been influenced by several events. In March 2026, the company reported Q4 and full-year 2025 financial results and a business update, highlighting the successful completion of the LIBERATE-1 study and promising preclinical data for a semaglutide implant. In May 2026, Q1 2026 financial results and a business update confirmed the SLIM-1 clinical trial for NPM-139 was on track for mid-year 2026. July 2026 saw Vivani Medical announce a non-exclusive agreement with Novo Nordisk to evaluate NPM-139 and its NanoPortal technology, and the CEO was featured in a CNBC interview. In August 2026, the company reported Q2 2026 financial results, noting the successful and early enrollment and dosing of all participants in the SLIM-1 Phase 1 trial for NPM-139, with top-line data expected in November 2026; additionally, its Cortigent subsidiary entered a definitive merger with ClearOne to form Cortigent Holdings. In September 2026, the company announced its participation in upcoming investor conferences. As of September 17, 2026, the stock price had decreased by 16.55% in the past month and 17.69% over the last 12 months, with a year-to-date return of -1.63%.